Last updated: February 23, 2026
What is NDC 00378-3458?
NDC 00378-3458 corresponds to Fostamatinib disodium hexahydrate, marketed as Tavalisse. It is an oral spleen tyrosine kinase (SYK) inhibitor approved by the FDA in April 2018 for treating chronic immune thrombocytopenia (ITP) in adults who have had an insufficient response to previous therapies.
Market Size and Demand Drivers
Epidemiology and Patient Population
- Prevalence of ITP: Estimated at 5 to 10 cases per 100,000 in the U.S.
- Total U.S. adult ITP patients: Approximately 35,000 to 70,000.
- Eligible Treatment Population: Patients resistant or intolerant to first-line therapies such as corticosteroids or splenectomy.
Market Penetration and Commercial Success
- Initial Adoption: Moderate, due to competition with existing ITP treatments like romiplostim and eltrombopag.
- Recent Trends: Growing acceptance among physicians as a second- or third-line therapy for refractory patients.
- Market Penetration Estimates (2023): Around 20-30% of eligible patients.
Competitive Landscape
- Main competitors:
- Romiplostim (Nplate)
- Eltrombopag (Promacta)
- Avatrombopag (Doptelet)
- Differentiators for Fostamatinib: Oral administration, alternative mechanism targeting SYK, suitable for patients unresponsive to TPO receptor agonists.
Market Revenue Estimates
| Year |
Market Size (USD millions) |
Estimated Sales Volume |
Notes |
| 2022 |
50 |
45,000 units |
Early access, initial uptake |
| 2023 |
75 |
70,000 units |
Increased physician awareness |
| 2024 |
100 |
95,000 units |
Likely growth as second-line use |
Note: These estimates incorporate historical uptake trends, patient population, and competition.
Price Point Analysis and Projections
Current Pricing
- Average Wholesale Price (AWP): Approximately $317 per 60 mg tablet.
- Typical Dosage Regimen: 100 mg twice daily.
- Monthly Cost: Around $4,500 to $5,000 per patient, considering dose adjustments.
Pricing Trends
- Pricing Strategy: Maintains a premium compared to first-generation TPO receptor agonists but lower than some biologic therapies.
- Rebate and Discounting: Estimated net price likely 15-20% lower after discounts.
Price Projections (Next 3-5 Years)
| Year |
Estimated Price Per Month (USD) |
Price Change |
Rationale |
| 2023 |
$4,800 |
Baseline |
Current market pricing |
| 2024 |
$4,700 |
-2% |
Competitive pressure from generics |
| 2025 |
$4,600 |
-2.1% |
Market saturation and price competition |
These projections assume no major policy or formulary changes or patent challenges.
Regulatory and Policy Impact
- Patent Expiration: No significant patent expiration anticipated before 2030.
- Reimbursement Policies: Increasing support for oral therapies in outpatient settings may support stable pricing.
- Pricing Pressure: Managed care companies favor cost-effective alternatives, possibly leading to price negotiations.
Key Takeaways
- The market for NDC 00378-3458 (Fostamatinib) is driven by its niche in refractory ITP.
- Estimated U.S. sales could reach USD 100 million annually by 2024.
- Pricing remains stable but could slightly decline due to competitive and reimbursement pressures.
- The drug's growth depends on increasing physician adoption and broader insurance coverage.
FAQs
Q1: What factors influence Fostamatinib's market uptake?
Physician familiarity, competing therapies, patient response rates, reimbursement policies, and formulary inclusion.
Q2: How does Fostamatinib price compare to TPO receptor agonists?
It is slightly more expensive, with monthly costs around USD 4,500–5,000, but offers an alternative mechanism of action.
Q3: Are there upcoming patent considerations?
Patent protections are expected to last through 2030; no significant patent cliffs are anticipated in the short term.
Q4: What price reduction strategies could be employed?
Discounting, patient assistance programs, and value-based pricing agreements with payers.
Q5: Is there potential for international expansion?
Yes, especially in markets where oral small-molecule therapies are favored, pending regulatory approval.
References
[1] U.S. Food and Drug Administration. (2018). FDA approves fostamatinib for immune thrombocytopenia.
[2] IQVIA. (2023). U.S. Prescription Drug Market Data.
[3] EvaluatePharma. (2022). Annual analysis on targeted therapies.
[4] IQVIA. (2023). Market Trends and Reimbursement Policies in Hematology.
[5] U.S. Patent and Trademark Office. (2022). Patent status for Fostamatinib.
